irinotecan has been researched along with etoposide in 297 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 37 (12.46) | 18.2507 |
| 2000's | 130 (43.77) | 29.6817 |
| 2010's | 109 (36.70) | 24.3611 |
| 2020's | 21 (7.07) | 2.80 |
| Authors | Studies |
|---|---|
| Akiyama, S; Baba, M; Furukawa, T; Nitanda, T; Okamoto, M; Sugimoto, Y; Wang, X | 1 |
| Baguley, BC; Deady, LW; Denny, WA; Rodemann, T; Zhuang, L | 1 |
| Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Erlenkamp, G; Hilgeroth, A; Krug, M; Schächtele, C; Sippl, W; Totzke, F | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Dong, G; Guo, Z; Miao, Z; Sheng, C; Wang, S; Yao, J; Zhang, W; Zhang, Y | 1 |
| Chaniyara, R; Chen, CH; Chen, CW; Chien, SI; Chou, TC; Kakadiya, R; Lee, TC; Lin, LF; Shah, A; Su, TL; Tala, S; Tsai, TH; Zang, X | 1 |
| de Carvalho, JE; de Fatima Cepa Matos, M; de Oliveira Figueiredo, P; Garcez, FR; Garcez, WS; Perdomo, RT | 1 |
| Chang, LC; Goto, M; Hung, HY; Kuo, DH; Kuo, SC; Lee, KH; Liu, YQ; Morris-Natschke, SL; Nan, X; Pan, SL; Qian, K; Teng, CM; Wang, CY; Wang, MJ; Wu, TS; Wu, YC; Yang, JS; Yang, L; Yang, XM; Zhao, XB; Zhao, YL | 1 |
| Burckhardt, G; Flörl, S; Hagos, Y; Kühne, A; Marada, VV | 1 |
| Bae, SY; Hong, JY; Jung, C; Kang, SS; Lee, SK; Park, HJ | 1 |
| Fischer, C; Hetterling, G; Kliem, M; Micikas, RJ; Plauth, A; Rousseau, M; Sauer, S; Schroeder, FC; Siems, K; Weidner, C; Wowro, SJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chang, SM; Chen, TL; Christian, W; Detroja, D; Hwang, MJ; Lee, TC; Lin, YW; Pidugu, HB; Shah, A; Su, TL; Suen, CS; Wu, MH | 1 |
| Cui, Z; Ji, S; Kuang, Y; Li, K; Lin, Y; Qiao, X; Song, W; Tang, S; Ye, M; Yu, S | 1 |
| Gao, F; Wang, T; Xiao, J; Zhang, X | 1 |
| Abrantes, AM; Botelho, MF; Costa, SC; Gomes, AR; Gonçalves, AC; Pires, AS; Roleira, FMF; Silva, ET; Varela, CL | 1 |
| Dou, X; Huang, H; Jiang, L; Jiao, N; Jin, H; Jin, Z; Li, Z; Liu, Y; Liu, Z; Sun, X; Zhang, L; Zhu, G; Zou, Y | 1 |
| Dai, X; Jiang, T; Li, J; Qi, X; Wu, G; Yin, R; Yu, R; Zhang, G | 1 |
| Kato, M; Takada, S; Takayama, S | 1 |
| Fukuoka, M; Hirashima, T; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Takada, M; Tsukada, H; Yana, T | 1 |
| Arioka, H; Eguchi, K; Karato, A; Kunikane, H; Nishio, M; Ohe, Y; Oshita, F; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Capranico, G; D'Incalci, M; Garattini, S; Giaccone, G; Zunino, F | 1 |
| Ishihara, H; Itamochi, H; Kigawa, J; Minagawa, Y; Terakawa, N | 1 |
| Arioka, H; Eguchi, K; Karato, A; Nakashima, H; Ohe, Y; Oshita, F; Shinkai, T; Tamura, T; Uenaka, K; Yamamoto, N | 1 |
| Eguchi, K; Kanzawa, F; Karato, A; Kubota, N; Nishio, K; Ohe, Y; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Akiyaya, S; Ito, K; Kodera, Y; Kondou, K; Nagai, S; Satta, T; Takagi, H; Yamauchi, M | 1 |
| Kohno, K; Kuwano, M; Matsuo, K; Sato, S; Tanimura, H; Uchiumi, T; Yamada, Y | 1 |
| Ariyoshi, Y; Hida, T; Miyara, H; Morishita, M; Nishida, K; Sugiura, T; Takahashi, T; Ueda, R | 1 |
| Hasumi, K; Shimizu, Y; Umezawa, S | 1 |
| Ardouin, P; Bénard, J; Bissery, MC; Boland, I; Bressac-de-Paillerets, B; Gouyette, A; Gyergyay, F; Morizet, J; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM | 1 |
| Hidaka, H; Minamino, T; Miyamoto, K; Nakamura, S; Nomura, M; Wakusawa, S | 1 |
| Abe, S; Fujita, A; Hayashi, I; Kawakami, Y; Kurita, Y; Matsuda, T; Nakabayashi, T; Nishiwaki, Y; Noda, K; Oshita, F; Saijo, N; Suzuki, S; Takahashi, S; Tamura, T; Tobise, K; Tsuchiya, S | 1 |
| Kojima, Y; Kotake, T; Maeda, O; Miki, T; Nonomura, N; Okuyama, A; Saiki, S; Sawada, M | 1 |
| Cowan, KH; Fukuda, M; Ikeda, K; Kohno, S; Matsuo, I; Nakano, R; Narasaki, F; Oka, M; Soda, H; Takatani, H; Terashi, K; Tomonaga, M | 1 |
| Kizaki, H; Oguro, M; Onishi, Y | 1 |
| Furukawa, M; Harada, T; Kuwano, M; Tanaka, T | 1 |
| Murray, N | 1 |
| Negoro, S | 2 |
| Ando, M; Eguchi, K; Hojo, N; Kakinuma, R; Kasai, T; Kodama, T; Kubota, K; Kurata, T; Matsumoto, T; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Tamura, T; Yamamoto, N | 1 |
| Aoyagi, K; Aoyagi, Y; Asao, T; Okazaki, S; Sano, M; Utsugi, T; Wierzba, K; Yamada, Y | 1 |
| Cheng, X; Irie, T; Itamochi, H; Kanamori, Y; Kigawa, J; Minagawa, Y; Terakawa, N | 1 |
| Sakata, Y; Tsushima, K | 1 |
| Araki, S; Asakura, R; Hojo, K; Itoh, A; Kawahara, M; Konishi, T; Nouchi, T; Takeda, Y; Teruya, M | 1 |
| Chang, L; Ogita, S; Tanaka, T; Umesaki, N | 1 |
| Rowinsky, EK; Siu, LL | 1 |
| Ara, G; Chan, V; Eder, JP; Northey, D; Rizvi, N; Teicher, BA; Wong, J; Wong, YW | 1 |
| Adhikari, D; Banerjee, D; Bertino, JR; Fu, JZ; Schnieders, B; Zhao, SC | 1 |
| Igarashi, T; Kobayashi, Y; Murayama, T; Ohtsu, T; Sasaki, Y; Tobinai, K | 1 |
| Fukuoka, M; Hirashima, T; Kawase, I; Kobayashi, M; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Sawaguchi, H; Tada, T; Takeda, K; Takifuji, N; Ushijima, S; Yana, T | 1 |
| Abe, S; Hayashi, I; Kawakami, Y; Kurita, Y; Matsuda, T; Nakabayashi, T; Nishiwaki, Y; Saijo, N; Suzuki, S; Takahashi, T; Tamura, T; Yamamoto, N | 1 |
| Cheshire, PJ; Hallman, JD; Houghton, JA; Houghton, PJ; Li, Y; Luo, X; Lutz, L | 1 |
| Ajani, JA | 1 |
| Armand, JP; Couteau, C | 1 |
| Fujiwara, Y; Isobe, T; Katoh, O; Kurata, T; Miyazaki, M; Oguri, T; Ohashi, N; Takahashi, T; Yamakido, M; Yokozaki, M | 1 |
| Ekimoto, H; Mashiba, H; Matsumoto, S; Okamoto, K | 1 |
| Groshen, S; Keshelava, N; Reynolds, CP | 1 |
| Boisdron-Celle, M; Boulanger, N; Gamelin, E | 1 |
| Bigg, DC; Bronckart, Y; Chaboteaux, C; da Costa, PM; Decaestecker, C; Gordover, L; Harper, L; Kiss, R; Lavergne, O; Lesueur-Ginot, L; Malonne, H; Philippart, P | 1 |
| Arimoto, J; Bessho, T; Furukawa, T; Hirai, I; Maebeya, S; Matsuyama, K; Naito, Y; Oura, S; Sakurai, T; Suzuma, T; Tanino, H; Yano, T; Yoshimasu, T | 1 |
| Masuda, N; Negoro, S | 1 |
| Fukuoka, M; Kudoh, S; Masuda, N; Negoro, S | 1 |
| Koshiishi, H; Takahashi, E; Tamamoto, F; Utsumi, K | 1 |
| Bukowski, RM; Ganapathi, MK; Ganapathi, R; Grabowski, DR; Tabata, M; Tabata, R | 1 |
| Hareyama, M; Imai, K; Itoh, F; Kakiuchi, H; Kobayashi, T; Sasaki, Y; Suzuki, H | 1 |
| Kobayashi, A; Yamaguchi, M | 1 |
| Fujishiro, M; Fukuda, H; Fukuda, M; Kunitoh, H; Nishiwaki, Y; Ohe, Y; Saijo, N; Sekine, I; Shinkai, T; Tamura, T | 1 |
| Bigg, D; Camara, J; Coulomb, H; Demarquay, D; Huchet, M; Lavergne, O; Lesueur-Ginot, L | 1 |
| Tamura, T | 1 |
| Bonomi, P; Shirazi, W | 1 |
| Belani, CP; Calvo, AR | 1 |
| Fukuoka, M | 1 |
| Inoue, A; Saijo, N | 1 |
| Kimura, T | 1 |
| Kumazaki, T; Nishiyama, M; Okamoto, R; Sekikawa, T; Takano, H; Tanaka, T; Tanimoto, K; Toyada, M; Ukon, K | 1 |
| Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
| Fukuoka, M; Kawahara, M; Mori, K; Negoro, S; Nishiwaki, Y; Noda, K; Saijo, N; Sugiura, T; Tamura, T; Watanabe, K; Yamamoto, S; Yokoyama, A | 1 |
| Carney, DN | 1 |
| Agata, H; Fujimoto, T; Hirota, T; Hori, T; Kawai, N; Kitagawa, S; Konno, K; Sawada, K; Tsurusawa, M | 1 |
| Amorino, GP; Cao, Q; Choy, H; Kim, JS; Pyo, H | 1 |
| Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Cummings, J; Jardine, L; Joel, SP; Okorokov, AL; te Poele, RH | 1 |
| Acquaviva, AM; Apicella, A; Di Matola, T; di Palma, A; Pensabene, M; Pignata, S; Ricchi, P; Ruggiero, G; Zanzi, D; Zarrilli, R | 1 |
| Berg, S; Bernstein, M; Blaney, SM; Cherrick, I; Kuttesch, N; Murry, DJ; Salama, V | 1 |
| Sandler, A | 1 |
| Akeshima, R; Iba, T; Itamochi, H; Kamazawa, S; Kanamori, Y; Kigawa, J; Sultana, H; Terakawa, N | 1 |
| Yokoyama, A | 1 |
| Nokihara, H; Ohe, Y | 1 |
| Arnt, CR; Chiorean, MV; Gores, GJ; Heldebrant, MP; Kaufmann, SH | 1 |
| Deguchi, N; Murai, M; Nonaka, S; Ueno, M; Yamazaki, R | 1 |
| Adams, R; Albritton, K; Coffin, C; Goldsby, R; Pulsipher, M; Wagner, L | 1 |
| Friberg, LE; Henningsson, A; Karlsson, MO; Maas, H; Nguyen, L | 1 |
| Turrisi, AT | 1 |
| Eguchi, K; Goto, K; Hojo, F; Kakinuma, R; Kodama, T; Kubota, K; Kunitoh, H; Matsumoto, T; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Tamura, T; Yoshimura, K | 1 |
| Fukuoka, M; Kudoh, S; Matsui, K; Mori, K; Nakano, T; Negoro, S; Nishiwaki, Y; Noda, K; Ohsaki, Y; Saijo, N; Sekine, I; Yokoyama, A | 1 |
| Aisner, J; Beers, S; Gounder, M; Licitra, EJ; Lin, Y; Musanti, R; Nelson, K; Poplin, E; Rajendra, R; Rubin, EH; Saleem, A; Schaaf, LJ; Smith, S; Thomas, C; Toppmeyer, D; Vyas, V | 1 |
| Blumenschein, GR; Fossella, FV; Glisson, BS; Johnson, FM; Komaki, R; Kurie, JM; Papadimitrakopoulou, VA; Peeples, BO; Pisters, KM | 1 |
| Langer, CJ | 2 |
| Blumenschein, GR; Feng, L; Fossella, FV; Glisson, BS; Johnson, FM; Komaki, R; Kurie, JM; Lee, JJ; Papadimitrakopoulou, VA; Peeples, BO; Pisters, KM | 1 |
| El-Deiry, WS; Wang, S | 1 |
| Saijo, N | 1 |
| Aibe, H; Asayama, Y; Honda, H; Irie, H; Kakihara, D; Matake, K; Nakamura, K; Nakayama, T; Nishie, A; Ohga, S; Tajima, T; Yamamoto, N; Yoshimitsu, K | 1 |
| Cheong, K; Chrystal, K; Harper, P | 1 |
| Andoh, T; Takahashi, N; Umemura, K; Yanase, K | 1 |
| Gillenwater, HH; Wolf, T | 1 |
| Nakanishi, Y; Uchino, J | 1 |
| Liu, WM; Propper, DJ; Scott, KA; Shahin, S | 1 |
| Kishida, T; Komiyama, M; Mori, T; Noguchi, M; Noguchi, Y; Ohnishi, M; Sawaguchi, K; Yabushita, H | 1 |
| Horiike, A; Saijo, N | 2 |
| Goto, K; Kakinuma, R; Kodama, T; Kubota, K; Kunitoh, H; Matsui, K; Matsumoto, T; Niho, S; Nishiwaki, Y; Nokihara, H; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Sugiura, T; Tamura, T; Yamamoto, N; Yoshida, K | 1 |
| Gräslund, A; Jarvet, J; Kogner, P; Lindskog, M; Spenger, C | 1 |
| Hatae, M; Nakamura, T; Onishi, Y | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hermann, R; Litchy, S; Morrissey, LH; Rodriguez, GI; Shaffer, DW; Yardley, DA | 1 |
| Adachi, M; Horichi, N; Ichikawa, I; Imai, T; Kashiwabara, Y; Kiuchi, Y; Kogo, M; Koichi, K; Murayama, J; Saito, Y | 1 |
| Sugiyama, T | 1 |
| André, A; Braekman, JC; Bruyneel, F; Darro, F; Decaestecker, C; Dewelle, J; El Yazidi, M; Guissou, P; Kiss, R; Nacoulma, O; Simon, G; Tuti, J; Van Quaquebeke, E | 1 |
| Hoshiai, H; Nakai, H; Watanabe, Y | 1 |
| Cho, KH; Han, JY; Kim, EA; Kim, HY; Lee, DH; Lee, JS; Lee, SY | 1 |
| Eimermacher, A; Flieger, D; Galle, PR; Geer, T; Gracien, E; Heike, M; Höhler, T; Junginger, T; Menges, M; Moehler, M; Siebler, J; Wein, A | 1 |
| Bamias, A; Briasoulis, E; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Kosmidis, P; Makatsoris, T; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Farmakis, D; Pectasides, D; Pectasides, M | 1 |
| Ariyoshi, Y; Fukuda, Y; Fukuoka, M; Isobe, T; Katakami, N; Komuta, K; Kudoh, S; Nakamura, S; Nakano, T; Takada, M; Takada, Y | 1 |
| Imamura, F; Kawahara, M; Kubota, K; Mori, K; Negoro, S; Nishiwaki, Y; Noda, K; Saijo, N; Sugiura, T; Tamura, T; Watanabe, K | 1 |
| Brodsky, I; Rosenbluth, JZ; Styler, MJ; Zak, D | 1 |
| Kaneda, T; Narita, Y; Suzuki, A; Takahashi, N; Tsunematsu, K | 1 |
| Fischer von Weikersthal, L; Hortig, P; Keilholz, U; Martus, P; Reeb, M; Schmittel, A; Schulze, K; Sebastian, M; Thiel, E | 1 |
| Akiyama, S; Furukawa, T; Gotanda, T; Haraguchi, M; Jueng, HC; Sakata, R; Shimamoto, Y; Sumizawa, T | 1 |
| Kawauchi, A; Miki, T; Mizutani, Y; Nakamura, T; Nomoto, T | 1 |
| Bai, T; Tanaka, T; Umesaki, N; Yukawa, K | 1 |
| Fukuoka, Y; Hasegawa, Y; Hitsuda, Y; Igishi, T; Kodani, M; Kurai, J; Miyata, M; Shimizu, E; Suyama, H; Touge, H; Yasuda, K | 1 |
| Iwashige, A; Kagami, S; Tsukada, J; Uramoto, H | 1 |
| Cloughesy, TF; Lai, A; Mischel, P; Nghiemphu, P; Pope, WB | 1 |
| Büchler, P; Ganten, TM; Haas, TL; Koschny, R; Schader, MB; Schulze-Bergkamen, H; Stremmel, W; Sykora, J; Untergasser, A; Walczak, H | 1 |
| Gandara, DR; Lara, PN; Natale, RB | 1 |
| Ansari, R; Beck, T; Bunn, PA; Byrne, M; Einhorn, L; Ellis, P; Guthrie, T; Hanna, N; Hariharan, S; Langer, C; Morrison, M; Sandler, A; Wang, B | 1 |
| Hasegawa, H; Miyagi, T; Nagasaki, A; Nakachi, S; Shinzato, O; Taira, N; Takasu, N; Tomoyose, T | 1 |
| Fournel, P | 1 |
| Inoue, H; Miyashita, T; Takemura, H; Ueda, T; Yoshida, A | 1 |
| Kawashima, O; Morishita, Y; Nagashima, T; Sugano, M | 1 |
| Danks, MK; Hatfield, MJ; Lee, RE; Potter, PM; Qi, J; Remack, JS; Virga, KG; Yoon, KJ | 1 |
| Anai, H; Anegawa, G; Honda, M; Kai, T; Kaneko, S; Masuda, T; Nakamura, Y; Ohta, R; Saeki, H; Yokoyama, S | 1 |
| Anderson, JR; Breitfeld, PP; Lager, JJ; Lyden, ER; Meyer, WH; Pappo, AS | 1 |
| Brunetto, AL; Castro, CG; Cruz, LB; Rech, A; Ribeiro, AS; Rosa, LG | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kobayashi, H; Mano, H; Tsunoda, S | 1 |
| Katakami, N | 1 |
| Butler, RN; Davidson, GP; Howarth, GS; Tooley, KL | 1 |
| Kamoto, T; Kawahara, T; Nishiyama, H; Ogawa, O; Yamamoto, S | 1 |
| Feun, LG; Heros, D; Herrera, C; Landy, H; Marini, A; Markoe, A; Robles, C; Savaraj, N | 1 |
| Ando, M; Eguchi, K; Fukuoka, M; Ichinose, Y; Kudoh, S; Matsui, K; Nakagawa, K; Negoro, S; Saito, H; Tada, T; Takada, M; Takada, Y; Tamura, K | 1 |
| Hashimoto, T; Izumi, Y; Kato, T; Kawada, K; Miura, A; Momma, K; Oota, M | 1 |
| Aoyama, C; Hosoya, R; Kamiya, T; Kato, I; Manabe, A; Ogawa, C; Ozawa, M; Takahashi, H; Takusagawa, A; Yokoyama, K | 1 |
| Ono, A; Yamamoto, N | 1 |
| Harita, S; Hotta, K; Kiura, K; Kuyama, S; Okimoto, N; Segawa, Y; Shinkai, T; Tabata, M; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Yoneda, S | 1 |
| Chijiiwa, K; Igarashi, T; Izumi, H; Kohno, K; Miyamoto, N; Niina, I; Okayasu, R; Onitsuka, T; Shiota, M; Torigoe, T; Uchiumi, T; Wakasugi, T | 1 |
| Kamura, T; Kitagawa, R; Nishio, S; Shouji, T; Sugiyama, T; Ushijima, K; Yoshizaki, A | 1 |
| Allen, WL; Galligan, L; Johnston, PG; Longley, DB; Rogers, KM; Sakai, H; Thomas, M; Wilson, TR | 1 |
| Fujimoto, K; Hirao, Y; Matsushita, C; Miyake, M; Tanaka, M; Tanaka, N | 1 |
| Hotta, K; Ichimura, K; Kiura, K; Matsuoka, J; Osawa, M; Tabata, M; Takigawa, N; Tanimoto, M | 1 |
| Chang, J; Cheon, SH; Cho, BC; Choi, HJ; Jung, JY; Kim, JH; Kim, SK; Shin, SJ; Sohn, JH | 1 |
| Fujiwara, Y; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Tsuta, K; Yamada, K; Yamamoto, N | 1 |
| Briasoulis, E; Dimopoulos, MA; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Pectasides, D; Samantas, E; Skarlos, D; Syrigos, K | 1 |
| Seto, T | 1 |
| Bai, ZG; Jiang, L; Liu, YL; Ma, B; Mi, DH; Tan, JY; Tian, JH; Yang, KH | 1 |
| Arimura, K; Armstrong, DL; Bhattacharjee, MB; Boerkoel, CF; Champoux, JJ; Choi, K; Deguchi, K; Hirano, R; Huang, C; Inoue, K; Interthal, H; Izumo, S; Nakamura, T; Northrop, JL; Salih, MA; Takashima, H; Umehara, F | 1 |
| Cohen, RB; Dahlberg, S; Hidalgo, M; Johnson, DH; Lee, MW; Pandya, KJ; Schiller, JH | 1 |
| Isobe, H; Matsui, K; Mori, K; Nakagawa, K; Nishiwaki, Y; Nokihara, H; Saijo, N; Sekine, I; Takeda, K; Tamura, T | 1 |
| Chinen, T; Hirayasu, T; Ishikawa, K; Kawabata, T; Kawasaki, H; Kuniyoshi, M; Ogawa, K; Ohta, M; Oshiro, Y; Samura, H; Teruya, J; Teruya, T; Uehara, T; Yohena, T | 1 |
| Duh, MS; Lefebvre, P; Neary, M; Reynolds Weiner, J; Skarin, AT | 1 |
| Hirose, S; Hojo, T; Ikeuchi, S; Isobe, Y; Kinoshita, T; Kubochi, K; Matsumoto, S; Sadako, AT; Shien, T; Terada, K | 1 |
| Ito, N; Kamba, T; Kamoto, T; Kanematsu, A; Masui, K; Nakamura, E; Nishiyama, H; Ogawa, O; Soda, T; Watanabe, J; Yoshimura, K | 1 |
| Betta, PG; Catalano, A; Lazzarini, R; Moretti, S; Orecchia, S; Procopio, A | 1 |
| Aasebø, U; Bergman, B; Bremnes, R; Ek, L; Fluge, S; Hermes, A; Sederholm, C; Sörenson, S; Sundstrøm, S; Thaning, L; Vilsvik, J | 1 |
| Carleton, JE; Chansky, K; Crowley, J; Dakhil, SR; Gandara, DR; Jett, J; Kuebler, JP; Langer, CJ; Lara, PN; Lenz, HJ; Natale, R; Redman, MW | 1 |
| Pappo, A; Paulino, AC | 1 |
| Chelis, L; Christophyllakis, Ch; Georgoulias, V; Giassas, S; Kakolyris, S; Kalykaki, A; Kentepozidis, N; Kotsakis, A; Polyzos, A; Vamvakas, L; Vardakis, N; Xenidis, N | 1 |
| Glisson, BS; Johnson, FM | 1 |
| Adachi, M; Hirose, T; Nakamura, A; Ohnishi, T; Okuda, K; Yamaoka, T; Yashiki, C | 1 |
| Adachi, M; Hirose, T; Kusumoto, S; Nakamura, A; Ohmori, T; Shirai, T; Sugiyama, T; Yashiki, C | 1 |
| Blumenschein, GR; Feng, L; Fossella, FV; Glisson, BS; Johnson, FM; Karp, DD; Peeples, BO; Stewart, DJ; Uyeki, J; William, WN | 1 |
| Cardenal, F; Cisar, L; Domine, M; Gorbunova, V; Moiseyenko, V; Soria, JC; Szczesna, A; Thomas, M; Zatloukal, P; Zhang, X | 1 |
| Charpidou, A; Gkiozos, I; Makrilia, N; Stratakos, G; Syrigos, K; Tsagouli, S; Tsimpoukis, S; Vassias, A | 1 |
| Chu, Z; Huang, L; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Bodiagin, DA; Pokrovskiĭ, VS; Treshchalin, MI; Treshchalina, EM | 1 |
| Araki, M; Hasegawa, H; Itoh, M; Kodama, Y; Kuzushita, N; Mano, M; Mita, E; Morita, K; Nakazuru, S; Ohta, M; Ohta, T; Suemura, S; Sueyoshi, Y; Toyama, T; Yoshio, T; Yoshioka, C | 1 |
| Chansky, K; Crowley, J; Fukuda, H; Gandara, DR; Lara, PN; Natale, R; Redman, MW; Saijo, N; Shibata, T; Tamura, T | 1 |
| Cantor, A; Miley, D; Reddy, V; Robert, F; Rossman, J | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M | 1 |
| Guo, S; Liang, Y; Zhou, Q | 1 |
| Binder, D; Caca, K; Eberhardt, WE; Fischer von Weikersthal, L; Fischer, B; Fischer, JR; Gauler, TC; Hortig, P; Kaufmann, C; Keilholz, U; Link, H; Martus, P; Schmittel, A; Sebastian, M | 1 |
| Fujimoto, T; Kumagai, S; Kurachi, H; Mizunuma, H; Nakahara, K; Nishiyama, H; Omi, H; Shoji, T; Sugiyama, T; Takano, T; Takatori, E; Tase, T; Yaegashi, N; Yokoyama, Y; Yoshizaki, A | 1 |
| Asanuma, H; Hasegawa, T; Hirata, K; Hirohashi, Y; Inoda, S; Ishitani, K; Kondo, T; Morita, R; Nakatsugawa, M; Nishizawa, S; Sato, N; Takahashi, A; Tamura, Y; Terui, T; Torigoe, T; Tsuruma, T | 1 |
| Hirakawa, K; Miwa, A; Qiu, H; Yashiro, M; Zhang, X | 1 |
| Amin, NP; Camidge, DR; Gaspar, LE; Kavanagh, B; Miften, M; Raben, D; Rochford, N; Thornton, D | 1 |
| Bonnabry, P; Fleury-Souverain, S; Geiser, L; Hochstrasser, D; Nussbaumer, S; Sadeghipour, F; Veuthey, JL | 1 |
| Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W | 1 |
| Allen, PJ; Brady, MS; Busam, KJ; Chou, JF; Coit, DG; Fields, RC; Kraus, DH; Panageas, KS; Pulitzer, MP | 1 |
| Cheema, TA; Kanai, R; Kim, GW; Martuza, RL; Passer, B; Rabkin, SD; Wakimoto, H | 1 |
| Bhattacharyya, J; Hoshi, M; Kimura, A; Mihara, K; Ohtsubo, M; Sakai, A; Takei, Y; Takihara, Y; Yanagihara, K; Yasunaga, S | 1 |
| Bellot, GL; Koh, D; Tan, WH; Tay, LL; Wang, X | 1 |
| Jin, S; Shao, N; Zhu, W | 1 |
| Cho, YJ; Duk Lee, J; Go, SI; Hwang, YS; Jeong, YY; Kim, DC; Kim, HC; Ko, GH; Lee, GW; Lee, JH; Lee, JS; Oh, S; Yang, JW | 1 |
| Fukuda, H; Kamura, T; Katsumata, N; Konishi, I; Matsumoto, K; Saito, I; Shibata, T | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Guan, QL; Jiang, L; Mi, DH; Wang, J; Yang, KH | 1 |
| Furuya, K; Goto, T; Kato, M; Kita, T; Kudoh, K; Miyamoto, M; Sasaki, N; Takano, M; Watanabe, A; Yoshikawa, T | 1 |
| Ando, M; Gemma, A; Hino, M; Kobayashi, K; Kosaihira, S; Minegishi, Y; Miyanaga, A; Mizutani, H; Nomura, K; Noro, R; Okano, T; Seike, M; Yoshimura, A | 1 |
| Harada, D; Ichihara, E; Kiura, K; Kubo, T; Ninomiya, T; Ochi, N; Osawa, M; Takigawa, N; Tanimoto, M; Yamane, H | 1 |
| Basu, EM; Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Roberts, SS | 1 |
| Ansari, RH; Atkins, JN; Bogart, JA; Green, MR; Hodgson, LD; Kelley, MJ; Pang, H; Vokes, EE | 1 |
| Fragoulis, EG; Korbakis, D; Scorilas, A | 1 |
| Herbst, RS; Isobe, T; Itasaka, S; Jacoby, JJ; Koo, PJ; Morgensztern, D; O'Reilly, MS; Onn, A; Shibuya, K; Shintani, T; Wu, W | 1 |
| Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Wakuda, K; Yamamoto, N | 1 |
| Bauer, D; Biassoni, V; Casanova, M; Catania, S; De Pava, MV; Gandola, L; Indini, A; Massimino, M; Modena, P; Pecori, E; Podda, M; Polastri, D; Rampini, P; Schiavello, E | 1 |
| Jett, JR; Kalemkerian, GP; Kesler, KA; Schild, SE | 1 |
| Ahn, HS; Kang, HJ; Kim, H; Lee, JW; Park, JD; Park, KD; Shin, HY | 1 |
| Levy, B; Saxena, A; Schneider, BJ | 1 |
| Elsing, C; Hannig, CV; Herrmann, C; Herrmann, T; Jäger, D; Stremmel, W | 1 |
| Aisner, J; Axelrod, RS; Dahlberg, SE; Gounder, M; Owonikoko, TK; Ramalingam, SS; Rausch, PG; Rubin, EH; Schiller, JH; Wang, XV | 1 |
| Harada, M; Hida, T; Imamura, F; Ishikura, S; Kawahara, M; Kubota, K; Matsui, K; Mizusawa, J; Nakagawa, K; Negoro, S; Nishio, M; Okamoto, H; Saijo, N; Sakai, H; Shibata, T; Shinkai, T; Takeda, K; Tamura, T; Yamamoto, N; Yokoyama, A | 1 |
| Chohnabayashi, N; Ishikawa, G; Jinta, T; Kitamura, A; Mochizuki, S; Nishimura, N; Suzuki, K; Tomishima, Y; Yamano, Y | 1 |
| Erbaykent-Tepedelen, B; Gonen-Korkmaz, C; Karamil, S; Korkmaz, KS | 1 |
| Asamura, H; Eba, J; Katayama, H; Kenmotsu, H; Niho, S; Shibata, T; Tamura, T; Tsuboi, M; Watanabe, S; Yamamoto, N | 1 |
| Arce-Lara, C; Kelley, MJ; Santana-Davila, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| Yano, S | 1 |
| Boku, N; Furuse, J; Ishido, K; Kasuga, A; Machida, N; Morizane, C; Nishina, T; Okusaka, T; Sudo, K; Takahashi, H; Tobimatsu, K; Yamaguchi, T | 1 |
| Kadowaki, M; Kohno, K; Kondo, S; Kubota, A; Okamura, S; Takase, K; Takeshita, M; Tanimoto, K; Yamasaki, S | 1 |
| Asamura, H; Fujiwara, Y; Horinouchi, H; Kanda, S; Kitazono, S; Mizugaki, H; Nokihara, H; Tamura, T; Tanaka, A; Tsuta, K; Yagishita, S; Yamamoto, N | 1 |
| Eba, J; Misumi, Y; Nakamura, K; Ohe, Y; Okamoto, H; Shibata, T; Shimokawa, T; Yamamoto, N | 1 |
| Kamura, T; Katsumata, N; Konishi, I; Matsumoto, K; Nakamura, K; Saitou, M; Satoh, T; Shibata, T; Takano, T; Yunokawa, M | 1 |
| Komune, S; Nakashima, T; Toh, S; Yamauchi, M; Yasumatsu, R | 1 |
| Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Okuyama, H; Shimizu, S; Takahashi, H; Ueno, H | 1 |
| Au-Yeung, TT; Fleisig, HB; Hukezalie, KR; Ludlow, AT; Thompson, CA; Wong, JM; Zhao, CR | 1 |
| Harada, M; Inoue, A; Ishida, T; Kinoshita, I; Maemondo, M; Mori, Y; Morikawa, N; Nakagawa, T; Nukiwa, T; Oizumi, S; Saito, R; Sugawara, S; Suzuki, T; Taima, K; Watanabe, H | 1 |
| Liang, G; Xu, T; Yang, L; Zhang, F | 1 |
| Fujisawa, M; Miyake, H; Nishikawa, M | 1 |
| Cacciola, NA; De Stefano, A; Federico, A; Forzati, F; Fusco, A; Malapelle, U; Pallante, P; Pellecchia, S; Rocco, D; Sepe, R | 1 |
| Chang, GJ; Crane, CH; Das, P; Feig, BW; Krishnan, S; Minsky, BD; Rashid, A; Skibber, JM; Voong, KR; Wolff, RA; Yao, JC | 1 |
| Allendorf, DJ; Bordoni, RE; Dixon, PM; Grant, SC; Jerome, ML; Miley, DK; Reddy, VB; Robert, F; Saleh, MN; Singh, KP | 1 |
| Anderson, JR; Arndt, CA; Hawkins, DS; Lyden, E; Meyer, WH; Michalski, JM; Parham, DM; Rodeberg, DA; Weigel, BJ | 1 |
| Hur, GY; Kang, EJ; Kang, KH; Kim, JS; Lee, SY; Min, KH; Oh, SC; Seo, JH; Shim, JJ | 1 |
| Debus, J; Ho, AD; Huber, PE; Nicolay, NH; Perez, RL; Rühle, A; Saffrich, R; Schmezer, P; Sisombath, S; Trinh, T; Weber, KJ | 1 |
| Agama, K; Brünner, N; Doroshow, JH; Jensen, NF; Knudsen, BR; Pfister, TD; Pommier, Y; Roy, A; Rømer, MU; Smith, DH; Stenvang, J; Zhang, HL | 1 |
| Chen, L; Chen, Y; Feng, X; Peng, L; Wang, J; Zhong, D | 1 |
| Goto, K; Hida, T; Imamura, F; Kiura, K; Kozuki, T; Mori, K; Nakagawa, K; Nishio, M; Ohe, Y; Okamoto, H; Satouchi, M; Sawa, T; Seto, T; Shibata, T; Takahashi, T; Takeda, K; Tamura, T; Tanaka, H; Yoshimura, N | 1 |
| Asao, T; Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Kitahara, S; Nokihara, H; Ohe, Y; Okuma, HS; Sunami, K; Yamamoto, N | 1 |
| Gress, TM; Rinke, A | 1 |
| Chen, L; Chen, Y; Zhong, D | 1 |
| Han, D; Li, S; Ren, X; Shang, W; Sun, L; Wang, G; Xu, L | 1 |
| DeLuca, JG; Herman, JA; Lee, E; Paddison, P; Pain, M; Toledo, CM; Wang, H; Yong, RL; Zhu, J | 1 |
| Li, Q; Sun, L; Wen, F; Zhang, P; Zheng, H; Zhou, J; Zhou, K | 1 |
| Fukuda, M; Hosokawa, M; Iwakawa, S; Masuda, A; Tanaka, S; Ueda, K | 1 |
| Fukui, T; Igawa, S; Katagiri, M; Kubota, M; Kurahayashi, S; Mitsufuji, H; Naoki, K; Nishinarita, N; Okuma, Y; Ono, T; Ozawa, T; Sasaki, J; Shirasawa, M; Sone, H; Sugimoto, A; Sugita, K | 1 |
| Choi, JH; Hahn, S; Heo, DS; Jang, JS; Kang, JH; Kim, BS; Kim, DW; Kim, HG; Kim, HK; Kim, JH; Kim, JS; Kim, SW; Kwon, JH; Lee, KH; Park, K; Ryoo, HM; Shin, SW | 1 |
| Chen, J; Fan, Y; Hong, R; Ma, F; Ou, K; Sang, D; Wang, J; Xu, B; Yuan, P; Zhai, X; Zhao, C | 1 |
| Azuma, K; Hoshino, T; Imamura, Y; Ishii, H; Kinoshita, T; Matsuo, N; Naito, Y; Tokito, T; Yamada, K | 1 |
| Brandetti, E; Cifaldi, L; Ognibene, M; Pezzolo, A; Pistoia, V; Veneziani, I | 1 |
| Darling, G; Durocher-Allen, LD; Ellis, PM; Goffin, JR; Ramchandar, K; Sun, A; Ung, YC | 2 |
| Chen, Y; Li, Q; Li, R; Ren, X; Xia, S; Xu, F | 1 |
| Acramel, A; Chouquet, T; Faure, P; Goldwirt, L; Jourdan, N; Madelaine, I; Mourah, S; Plé, A; Sauvageon, H | 1 |
| Horimatsu, T; Mishima, M; Miyamoto, S | 1 |
| Liu, JZ; Liu, WW; Liu, ZL; Wang, B | 1 |
| Nazha, B; Owonikoko, TK | 1 |
| Boudreaux, JP; Ramirez, RA; Thiagarajan, R; Thomas, KEH; Voros, BA; Woltering, EA | 1 |
| Auerbach, C; Cheron, R; Natarajan, E; Pashankar, F | 1 |
| Chalasani, P; Livingston, RB; Reed, D; Segar, JM; Stopeck, A | 1 |
| Brohl, AS; Cubitt, CL; Fridley, B; Kahen, E; Reed, DR; Welch, D | 1 |
| Belousov, MV; Gur'ev, AM; Lopatina, KA; Razina, TG; Sadrikina, LA; Safonova, EA; Zueva, EP | 1 |
| De Petris, L; Fang, F; Lewensohn, R; Pettersson, A; Tendler, S; Viktorsson, K; Zhan, Y | 1 |
| Li, J; Lu, M; Peng, Z; Shen, L; Wang, X; Zhang, P; Zhang, X; Zhou, J | 1 |
| Cai, LH; Chen, JP; Fu, WH; Hao, HK; He, QL; Huang, CM; Jiang, LX; Li, E; Li, HL; Li, P; Li, SL; Li, Y; Li, YX; Li, Z; Lin, JP; Lin, JX; Lin, W; Tian, YT; Xie, JW; Xu, YC; Xu, ZK; Xue, FQ; Zhao, G; Zhao, YJ; Zheng, CH; Zhou, XJ; Zhou, YB; Zhu, ZG; Zou, BB | 1 |
| Hirai, M; Ito, M; Kaneda, H; Morioka, I; Oba, D; Yagasaki, H | 1 |
| Lovetrue, B | 1 |
| de Carvalho Fraga, CA; de Souza, MG; Farias, LC; Guimarães, ALS; Guimarães, TA; Jones, KM; Xavier, GM | 1 |
| Afchain, P; Baudin, E; Desgrippes, R; Hadoux, J; Hautefeuille, V; Lepage, C; Lorgis, V; Monterymard, C; Scoazec, JY; Thuillier, F; Tougeron, D; Walter, T | 1 |
| Beberok, A; Maszczyk, M; Rok, J; Rzepka, Z; Wrześniok, D | 1 |
| Hamada, M; Ichikawa, D; Imaya, M; Kawashima, N; Kojima, S; Miwata, S; Muramatsu, H; Narita, A; Narita, K; Nishikawa, E; Nishio, N; Takahashi, Y; Wakamatsu, M; Yamamori, A; Yoshida, T | 1 |
| Fukuizumi, A; Gemma, A; Hirao, M; Matsuda, K; Miyanaga, A; Noro, R; Omori, M; Seike, M; Takano, N | 1 |
| Min, S; Zheng, Q; Zhou, Y | 1 |
| Boku, N; Furuse, J; Hiraoka, N; Honma, Y; Ikeda, M; Kataoka, T; Kato, K; Kitagawa, Y; Machida, N; Mizuno, N; Morizane, C; Nomura, S; Okano, N; Okusaka, T; Ozaka, M; Sato, T; Sekine, S; Taniguchi, H; Terashima, M; Ueno, M; Yamaguchi, K | 1 |
| Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
| Cruz, A; de-Castro-Ríos, A; Lema-Atán, JÁ; Lendoiro, E; López-Rivadulla, M; Paniagua-González, L | 1 |
| Huang, Z; Zhang, Y | 1 |
| Ni, J; Si, X; Wang, H; Zhang, L; Zhang, X | 1 |
| Akagi, K; Dotsu, Y; Fukuda, M; Gyotoku, H; Hayashi, F; Hisamatsu, Y; Ikeda, T; Kinoshita, A; Morinaga, R; Mukae, H; Nagashima, S; Nakatomi, K; Ogata, R; Ono, S; Senju, H; Shimada, M; Soda, H; Sugasaki, N; Tagawa, R; Takemoto, S; Taniguchi, H; Tomono, H; Umeyama, Y | 1 |
57 review(s) available for irinotecan and etoposide
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Quinolone hybrids and their anti-cancer activities: An overview.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Quinolones; Structure-Activity Relationship | 2019 |
DNA topoisomerase inhibitors.
Topics: Animals; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Interactions; Drug Resistance; Etoposide; Humans; Irinotecan; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1994 |
7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Survival; CHO Cells; Clinical Trials, Phase I as Topic; Cricetinae; DNA Topoisomerases, Type I; Drug Resistance; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Point Mutation; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1994 |
[DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Mutation; Neoplasms; Teniposide; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1997 |
["State-of-the-art" chemotherapy for small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vincristine | 1997 |
[Treatment of recurrent gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Doxorubicin; Drug Administration Schedule; Epirubicin; Etoposide; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Methotrexate; Mitomycin; Neoplastic Cells, Circulating; Peritoneal Neoplasms; Stomach Neoplasms | 1998 |
[Chemotherapy of gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Etoposide; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Methotrexate; Stomach Neoplasms | 1998 |
Chemotherapy for gastric carcinoma: new and old options.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Combinations; Enzyme Inhibitors; Etoposide; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
[Pharmacokinetic monitoring].
Topics: Antineoplastic Agents; Body Mass Index; Camptothecin; Colorectal Neoplasms; Drug Interactions; Drug Monitoring; Etoposide; Fluorouracil; Humans; Irinotecan; Liver; Paclitaxel; Topotecan | 2000 |
Irinotecan in small-cell lung cancer--Japanese trials.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Irinotecan; Japan; Lung Neoplasms; Radiation-Sensitizing Agents | 2000 |
New state of the art in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Irinotecan; Lung Neoplasms; Prognosis; Survival Rate | 2001 |
Chemoradiation in locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Forecasting; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Role of topoisomerase I inhibitors in small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Lung Neoplasms; Survival Analysis; Topoisomerase I Inhibitors | 2001 |
Recent advances in the chemotherapy of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
Irinotecan therapy for small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Japan; Lung Neoplasms; Survival Analysis; Topoisomerase I Inhibitors; United States | 2002 |
[Irinotecan].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Irinotecan; Lung Neoplasms | 2002 |
[Recent progress in the treatment of ED small cell lung cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Piperazines; Pyrimidines; Vincristine | 2002 |
Limited stage small cell lung cancer: treatment and therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Humans; Irinotecan; Lung Neoplasms; Prognosis; Treatment Outcome | 2003 |
The global role of irinotecan in the treatment of lung cancer: 2003 update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Japan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Staging; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; United States; Vindesine | 2003 |
Progress in treatment of small-cell lung cancer: role of CPT-11.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Topoisomerase I Inhibitors | 2003 |
Chemotherapy of small cell lung cancer: state of the art.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Etoposide; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Quality of Life; Survival Rate; Treatment Outcome | 2004 |
Treatment options for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiotherapy, Adjuvant; Risk Factors; Sex Distribution; Smoking; Survival Rate; Treatment Outcome; United States | 2004 |
[Treatment of platinum-resistant ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; DNA Damage; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Female; Gynecologic Surgical Procedures; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
[Second-line chemotherapy for recurrent ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Taxoids | 2005 |
Small-cell lung cancer: current therapy and novel agents.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis | 2005 |
Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Male; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Salvage Therapy; Testicular Neoplasms; Vinblastine | 2005 |
[Treatment of small cell lung cancer].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Lung Neoplasms; Survival Analysis | 2005 |
Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Femoral Neoplasms; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Osteosarcoma; Palliative Care; Salvage Therapy; Scalp; Skin Neoplasms; Thoracotomy | 2005 |
[Progress in therapy for testicular tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lymph Node Excision; Male; Paclitaxel; Taxoids; Testicular Neoplasms | 2006 |
[Chemotherapy for lung cancer patients].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Etoposide; Evidence-Based Medicine; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2006 |
Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Humans; Ifosfamide; Irinotecan; Lymphatic Metastasis; Male; Rhabdomyosarcoma; Survival Analysis; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome | 2006 |
[Lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Etoposide; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Pemetrexed; Taxoids | 2007 |
[Chemotherapy in lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate | 2007 |
Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: a metaanalysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Diarrhea; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Randomized Controlled Trials as Topic; Vomiting | 2007 |
A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Etoposide; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic | 2010 |
Complement and correction for meta-analysis of patients with extensive-stage small cell lung cancer managed with irinotecan/cisplatin versus etoposide/cisplatin as first-line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2011 |
An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Treatment Outcome | 2012 |
Systemic therapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Lung Neoplasms; Platinum; Recurrence; Small Cell Lung Carcinoma | 2013 |
[Programs for continuing medical education: B session; 4. Progress in lung cancer therapy].
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Crizotinib; Drug Discovery; Education, Medical, Continuing; Erlotinib Hydrochloride; Etoposide; Gefitinib; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma | 2014 |
Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Drug Administration Schedule; Etoposide; Everolimus; Humans; Irinotecan; Pancreatic Neoplasms | 2015 |
[First-line Chemotherapy for Extensive-disease Small Cell Lung Cancer:
A Network Meta-analysis].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Network Meta-Analysis; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2016 |
Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Gastrointestinal Neoplasms; Humans; Irinotecan; Ki-67 Antigen; Neoplasm Grading; Neuroendocrine Tumors; Practice Guidelines as Topic; Prognosis; Treatment Outcome | 2017 |
Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small-cell lung cancer patients with extensive disease: A network meta-analyses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Irinotecan; Network Meta-Analysis; Platinum; Small Cell Lung Carcinoma | 2017 |
Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis.
Topics: Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Diarrhea; Etoposide; Fatigue; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Nausea; Neoplasm Staging; Neutropenia; Odds Ratio; Proportional Hazards Models; Small Cell Lung Carcinoma; Thrombocytopenia; Vomiting | 2017 |
Guideline for the Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-line Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2018 |
Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Male; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2018 |
Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Etoposide; Hematologic Diseases; Humans; Incidence; Irinotecan; Lung Neoplasms; Nausea; Neoplasm Staging; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vomiting | 2018 |
Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Intestinal Neoplasms; Irinotecan; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Radiopharmaceuticals; Stomach Neoplasms | 2019 |
Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review.
Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2019 |
Pathways Related to the Anti-Cancer Effects of Metabolites Derived from Cerrado Biome Native Plants: An Update and Bioinformatics Analysis on Oral Squamous Cell Carcinoma.
Topics: Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Brazil; Carcinogenesis; Carcinoma, Squamous Cell; Cell Proliferation; Computational Biology; Etoposide; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mouth Neoplasms; Neoplasm Proteins; Paclitaxel; Plant Extracts; Plants, Medicinal; Vinblastine | 2021 |
A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Humans; Irinotecan; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Pemetrexed; Vinorelbine | 2022 |
69 trial(s) available for irinotecan and etoposide
| Article | Year |
|---|---|
Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diarrhea; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Half-Life; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Remission Induction; Thrombocytopenia | 1994 |
Phase I study of CPT-11 and etoposide in patients with refractory solid tumors.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Treatment Outcome | 1993 |
CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer.
Topics: Bayes Theorem; Camptothecin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Metabolic Clearance Rate | 1994 |
Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 1997 |
Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Enzyme Inhibitors; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1997 |
Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Interactions; Etoposide; Humans; Irinotecan; Liver; Lymphoma, Non-Hodgkin; Middle Aged; Topoisomerase I Inhibitors | 1998 |
Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Metabolic Clearance Rate; Middle Aged; Nausea; Recombinant Proteins; Reproducibility of Results; Vomiting | 1997 |
Induction of gamma-glutamylcysteine synthetase gene expression by platinum drugs in peripheral mononuclear cells of lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Blotting, Northern; Camptothecin; Carboplatin; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression; Glutamate-Cysteine Ligase; Humans; Irinotecan; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Polymerase Chain Reaction; RNA, Messenger; Statistics, Nonparametric; Tumor Cells, Cultured | 1999 |
[Combination of irinotecan hydrochloride and etoposide for treatment of refractory or relapsed small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local | 2000 |
[Evaluation of bronchial arterial infusion (BAI) for high risk lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Camptothecin; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intra-Arterial; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2000 |
Phase I study of a weekly infusion of irinotecan hydrochloride (CPT-11) and a 14-day continuous infusion of etoposide in patients with lung cancer: JCOG trial 9408.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged | 2000 |
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2002 |
[Phase I study with irinotecan hydrochloride (CPT-11) for advanced neuroblastoma].
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child, Preschool; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Irinotecan; Neuroblastoma | 2001 |
Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.
Topics: Antineoplastic Agents; Camptothecin; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Lung Neoplasms; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2002 |
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Diarrhea; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival; Thrombocytopenia | 2003 |
Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Survival Rate | 2003 |
Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cisplatin; Cohort Studies; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2003 |
Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Treatment Outcome | 2003 |
Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Analysis; Treatment Outcome | 2003 |
Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Enzyme Inhibitors; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Rate; Topoisomerase I Inhibitors | 2004 |
Irinotecan in advanced lung cancer: focus on North American trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; North America; Radiotherapy, Adjuvant; Ribonucleotide Reductases; Survival Rate; Taxoids; Topoisomerase I Inhibitors; Vindesine | 2004 |
Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Salvage Therapy; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2004 |
Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Treatment Outcome | 2004 |
Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Dose-Response Relationship, Radiation; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagogastric Junction; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Levoleucovorin; Male; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Analysis | 2005 |
Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Etoposide; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Treatment Outcome | 2005 |
Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Time Factors; Treatment Outcome | 2005 |
A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2006 |
Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Survival Rate | 2006 |
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2006 |
Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Cohort Studies; Etoposide; Female; Humans; Ifosfamide; Irinotecan; Low-Level Light Therapy; Male; Methotrexate; Mouth Mucosa; Neoplasms; Nutritional Status; Oral Hygiene; Severity of Illness Index; Stomatitis; Treatment Outcome | 2007 |
Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Etoposide; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Teniposide; Tomography, X-Ray Computed | 2007 |
Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Disease-Free Survival; Etoposide; Female; Fever; Humans; Infections; Irinotecan; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy Dosage; Radiotherapy, Adjuvant; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2006 |
A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prospective Studies; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2007 |
Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Pilot Projects; Taxoids | 2007 |
Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.
Topics: Adult; Aged; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2007 |
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Remission Induction; Sirolimus; Survival Rate; Treatment Outcome | 2007 |
Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate | 2008 |
Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Analysis | 2008 |
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Diarrhea; Etoposide; Female; Glucuronosyltransferase; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pharmacogenetics; Polymorphism, Single Nucleotide; Risk Factors; Small Cell Lung Carcinoma | 2009 |
Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
Topics: Aged; Camptothecin; Cisplatin; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy, Adjuvant; Small Cell Lung Carcinoma | 2010 |
Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma | 2010 |
A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Humans; International Agencies; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Young Adult | 2010 |
Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Etoposide; Female; Germany; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2011 |
Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Phase II study of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer: Japan Clinical Oncology Group Study 0503.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Infusions, Intravenous; Irinotecan; Ovarian Neoplasms; Research Design; Taxoids | 2012 |
Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Severity of Illness Index; Small Cell Lung Carcinoma; Thrombocytopenia; Treatment Outcome | 2012 |
Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemoradiotherapy; Cisplatin; Confidence Intervals; Dehydration; Disease-Free Survival; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Small Cell Lung Carcinoma | 2013 |
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2014 |
Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2014 |
A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Clinical Protocols; Disease-Free Survival; Etoposide; Female; Humans; Incidence; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Second Primary; Patient Selection; Survival Analysis; Treatment Outcome | 2014 |
Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2014 |
A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Patient Selection; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2015 |
Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503).
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Taxoids; Young Adult | 2015 |
Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retreatment; Small Cell Lung Carcinoma; Survival Rate | 2015 |
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Brain Diseases, Metabolic; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Administration Schedule; Endonucleases; Etoposide; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitosis; Multiple Organ Failure; Pneumonia; Treatment Outcome; Weight Loss | 2015 |
Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Patient Selection; Radiotherapy, Adjuvant; Rhabdomyosarcoma; Risk Assessment; Risk Factors; Severity of Illness Index; Treatment Outcome; Vincristine | 2016 |
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2016 |
Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cost-Benefit Analysis; Etoposide; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2018 |
Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Republic of Korea; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2019 |
A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Etoposide; Female; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Topoisomerase I Inhibitors | 2019 |
Treatment patterns and survival outcomes for small-cell lung cancer patients - a Swedish single center cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Sweden; Treatment Outcome | 2020 |
Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms | 2020 |
FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Neuroendocrine; Etoposide; Female; Fluorouracil; Humans; Intestinal Neoplasms; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Oxaliplatin; Pancreatic Neoplasms; Platinum Compounds; Progression-Free Survival; Prospective Studies; Quality of Life; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2021 |
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Digestive System; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2022 |
Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Immune Checkpoint Inhibitors; Irinotecan; Lung Neoplasms; Platinum | 2023 |
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Disease Progression; Etoposide; Humans; Immunotherapy; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2023 |
171 other study(ies) available for irinotecan and etoposide
| Article | Year |
|---|---|
Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; CD4-Positive T-Lymphocytes; Cells, Cultured; Doxorubicin; Drug Resistance, Neoplasm; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Lamivudine; Microbial Sensitivity Tests; Neoplasm Proteins; Reverse Transcriptase Inhibitors; Zidovudine | 2003 |
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
Topics: Animals; Antineoplastic Agents; Cell Division; Drug Screening Assays, Antitumor; Humans; Mice; Naphthyridines; Neoplasm Transplantation; Neoplasms, Experimental; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors.
Topics: Antineoplastic Agents; Benzylamines; Cell Line, Tumor; Computer Simulation; Drug Discovery; Humans; Protein Binding; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1; Structure-Activity Relationship | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations.
Topics: Antineoplastic Agents, Phytogenic; Biological Products; Cell Line, Tumor; Drug Screening Assays, Antitumor; Evodia; Humans; Quinazolines; Structure-Activity Relationship | 2012 |
Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase I and II inhibition.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cross-Linking Reagents; DNA; Drug Screening Assays, Antitumor; Humans; Indoles; Indolizines; Intercalating Agents; Male; Mice; Mice, Nude; Neoplasm Transplantation; Rats; S Phase Cell Cycle Checkpoints; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Transplantation, Heterologous | 2013 |
Further constituents of Galianthe thalictroides (Rubiaceae) and inhibition of DNA topoisomerases I and IIα by its cytotoxic β-carboline alkaloids.
Topics: Alkaloids; Animals; Antigens, Neoplasm; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Humans; Lactose; MCF-7 Cells; Mice; Oligopeptides; Plant Roots; Rubiaceae; Topoisomerase Inhibitors | 2014 |
Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents.
Topics: Amidines; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; HCT116 Cells; Humans; KB Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Conformation; Neoplasms, Experimental; Structure-Activity Relationship; Sulfonamides; Topoisomerase I Inhibitors | 2014 |
Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Humans; Liver-Specific Organic Anion Transporter 1; Molecular Structure; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Peptides; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2015 |
Antitumor Activity of Americanin A Isolated from the Seeds of Phytolacca americana by Regulating the ATM/ATR Signaling Pathway and the Skp2-p27 Axis in Human Colon Cancer Cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; CDC2 Protein Kinase; Checkpoint Kinase 1; Checkpoint Kinase 2; Colonic Neoplasms; Dioxins; G2 Phase Cell Cycle Checkpoints; HCT116 Cells; Humans; Mice; Mice, Nude; Molecular Structure; Phytolacca americana; Protein Kinases; Seeds; Signal Transduction; Tumor Suppressor Protein p53 | 2015 |
Amorfrutin C Induces Apoptosis and Inhibits Proliferation in Colon Cancer Cells through Targeting Mitochondria.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Caspases; Cell Cycle Checkpoints; Cell Proliferation; Colonic Neoplasms; Drug Screening Assays, Antitumor; Female; G1 Phase Cell Cycle Checkpoints; Glycyrrhiza; HT29 Cells; Humans; Inhibitory Concentration 50; Male; Membrane Potential, Mitochondrial; Mitochondria; Molecular Structure; Morocco; Peroxisome Proliferator-Activated Receptors; Plant Roots; Reactive Oxygen Species; Salicylates; Structure-Activity Relationship | 2016 |
Novel indolizino[8,7-b]indole hybrids as anti-small cell lung cancer agents: Regioselective modulation of topoisomerase II inhibitory and DNA crosslinking activities.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; DNA; DNA Topoisomerases, Type II; Drug Design; Humans; Indoles; Lung Neoplasms; Mice; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays | 2017 |
Glycybridins A-K, Bioactive Phenolic Compounds from Glycyrrhiza glabra.
Topics: Animals; Antioxidants; Drug Screening Assays, Antitumor; Glycyrrhiza; Hep G2 Cells; Humans; Lipopolysaccharides; Macrophages; Mice; Molecular Structure; Monophenol Monooxygenase; NF-kappa B; Nitric Oxide; Phenols; Plant Roots; Plants, Medicinal; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Rhizome | 2017 |
Design, synthesis, and antitumor activity evaluation of steroidal oximes.
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Oxidative Stress; Oximes; Steroids; Structure-Activity Relationship; Tumor Cells, Cultured | 2021 |
Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: Computational simulation, biological evaluation and cancer combinational chemotherapy study.
Topics: Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; DNA-Binding Proteins; Humans; Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases | 2022 |
Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Lung Neoplasms; Small Cell Lung Carcinoma | 2022 |
Comparison of lesions induced by intra-articular injections of quinolones and compounds damaging cartilage components in rat femoral condyles.
Topics: Administration, Oral; Animals; Bleomycin; Camptothecin; Cartilage, Articular; Chondroitin Lyases; Ciprofloxacin; Collagenases; Cycloheximide; Ethylmaleimide; Etoposide; Fluorescent Dyes; Hydroxyurea; Injections, Intra-Articular; Iodoacetates; Iodoacetic Acid; Irinotecan; Levofloxacin; Male; Ofloxacin; Papain; Rats; Rats, Sprague-Dawley; Rhodamines; Topoisomerase I Inhibitors | 1994 |
Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells.
Topics: Camptothecin; Cisplatin; Drug Resistance; Etoposide; Glutathione; HeLa Cells; Humans; In Vitro Techniques; Irinotecan; Methionine | 1994 |
Growth inhibition of human gastrointestinal cancer xenograft lines by treatment with CPT-11 and VP-16.
Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Etoposide; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous; Tumor Cells, Cultured | 1993 |
Enhanced expression of the DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer KB cells.
Topics: Camptothecin; DNA Topoisomerases, Type II; Etoposide; Gene Expression; Hot Temperature; Humans; Irinotecan; KB Cells; Neoplasms; RNA, Messenger; Teniposide | 1993 |
Modification of chemo-radiosensitivity of a human lung cancer cell line by introduction of the glutathione S-transferase pi gene.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Doxorubicin; Etoposide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutathione Transferase; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Radiation Tolerance; Tumor Cells, Cultured | 1996 |
[The results of chemosensitivity test for clear cell adenocarcinoma of the ovary].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Irinotecan; Mitomycin; Ovarian Neoplasms | 1996 |
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cisplatin; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Female; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; Neuroectodermal Tumors, Primitive; Neuroectodermal Tumors, Primitive, Peripheral; Paclitaxel; Thiotepa; Topoisomerase I Inhibitors; Transplantation, Heterologous | 1996 |
Inhibition of P-glycoprotein-dependent multidrug resistance by an isoquinolinesulfonamide compound H-87 in rat ascites hepatoma AH66 cells.
Topics: Affinity Labels; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Camptothecin; Dihydropyridines; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Irinotecan; Isoquinolines; Protein Binding; Protein Kinase Inhibitors; Rats; Sulfonamides; Tritium; Tumor Cells, Cultured; Vinblastine | 1996 |
Antitumor effect of CPT-11, a camptothecin derivative, on human testicular tumor xenografts in nude mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Teratocarcinoma; Testicular Neoplasms; Topoisomerase I Inhibitors; Transplantation, Heterologous; Vinblastine | 1997 |
The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers.
Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; Doxorubicin; Etoposide; Genes, MDR; Humans; Irinotecan; Mitomycin; Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured; Verapamil; Vincristine | 1996 |
A lymphoma cell line resistant to 4-piperidinopiperidine was less sensitive to CPT-11.
Topics: Antineoplastic Agents; Camptothecin; Cell Division; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Lymphoma, T-Cell; Piperidines; Tumor Cells, Cultured | 1997 |
New drugs for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Vincristine | 1997 |
Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Humans; Indenes; Indoles; Irinotecan; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Experimental; Pyridines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1997 |
Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; HeLa Cells; Humans; Irinotecan; Isoenzymes; Neoplasm Proteins; Tumor Cells, Cultured | 1997 |
Clonal analysis of cancer cells that survived anticancer drug treatment.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Cell Survival; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Humans; Irinotecan; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1997 |
A risk-benefit assessment of irinotecan in solid tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Colorectal Neoplasms; Diarrhea; Drug Therapy, Combination; Etoposide; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Risk Assessment | 1998 |
Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Death; DNA, Neoplasm; Doxorubicin; Drug Interactions; Etoposide; Female; Irinotecan; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; RNA, Messenger; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1998 |
Role of E2F-1 in chemosensitivity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carrier Proteins; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Survival; Cloning, Molecular; Culture Media, Serum-Free; DNA-Binding Proteins; Doxorubicin; E2F Transcription Factors; E2F1 Transcription Factor; Etoposide; Fibrosarcoma; Humans; Irinotecan; Paclitaxel; Recombinant Proteins; Retinoblastoma-Binding Protein 1; Tetrahydrofolate Dehydrogenase; Transcription Factor DP1; Transcription Factors; Transfection; Tumor Cells, Cultured | 1998 |
Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis | 1998 |
Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Rhabdomyosarcoma; Transplantation, Heterologous | 1996 |
[Evaluation of antitumor activity of etoposide administered orally for 21 consecutive days against human uterine cancer subcutaneous and/or orthotopic xenografts in nude mice].
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Floxuridine; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Skin; Transplantation, Heterologous; Uterine Neoplasms | 1999 |
Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
Topics: Antineoplastic Agents; Camptothecin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Neuroblastoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Topics: Antineoplastic Agents; Biopsy; Camptothecin; Cell Division; Colon; Colonic Neoplasms; Culture Techniques; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Thymidine; Topoisomerase I Inhibitors; Topotecan; Tritium; Tumor Cells, Cultured | 2000 |
[Histoculture drug response assay on non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mitomycin; Tumor Cells, Cultured | 2000 |
Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma.
Topics: Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA; DNA Damage; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; Humans; I-kappa B Proteins; Irinotecan; Leupeptins; Lung Neoplasms; NF-kappa B; NF-KappaB Inhibitor alpha; Paclitaxel; Peptide Hydrolases; Proteasome Endopeptidase Complex; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
Identification of genes highly expressed in G2-arrested Chinese hamster ovary cells by differential display analysis.
Topics: Animals; Arylamine N-Acetyltransferase; Camptothecin; CHO Cells; Cloning, Molecular; Cricetinae; DNA; DNA Damage; DNA, Complementary; Enzyme Inhibitors; Etoposide; Eukaryotic Initiation Factor-4A; G2 Phase; Gene Expression; Irinotecan; Isoenzymes; Nucleic Acid Synthesis Inhibitors; Peptide Initiation Factors; Ribosomal Proteins; RNA, Messenger; Topoisomerase I Inhibitors; X-Rays | 2000 |
[Three cases of liver metastasis of colon cancer responding to systemic combination chemotherapy utilizing CPT-11].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Irinotecan; Liver Neoplasms; Male; Tegafur; Uracil | 2000 |
The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Catalysis; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Nucleic Acid Synthesis Inhibitors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2000 |
In vitro schedule dependency in the treatment of topoisomerase I and II inhibitor.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2001 |
Unique action determinants of double acting topoisomerase inhibitor, TAS-103.
Topics: Aminoquinolines; Antineoplastic Agents, Phytogenic; Blotting, Northern; Blotting, Western; Buthionine Sulfoximine; Camptothecin; Drug Resistance; Enzyme Inhibitors; Etoposide; Fungal Proteins; Glutamate-Cysteine Ligase; Glutathione; GTP-Binding Proteins; Humans; Indenes; Irinotecan; Mitochondrial Proteins; RNA, Messenger; Saccharomyces cerevisiae Proteins; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2001 |
Lung cancer--time to move on from chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Smoking; Survival Rate | 2002 |
[Globalization of anti-cancer therapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms | 2002 |
DNA damage is able to induce senescence in tumor cells in vitro and in vivo.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; beta-Galactosidase; Breast Neoplasms; Camptothecin; Cell Cycle; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Damage; Etoposide; Humans; Irinotecan; Neoadjuvant Therapy; Tumor Suppressor Protein p53 | 2002 |
Effect of non-steroidal anti-inflammatory drugs on colon carcinoma Caco-2 cell responsiveness to topoisomerase inhibitor drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Caco-2 Cells; Camptothecin; Cell Survival; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Nitrobenzenes; Sulfonamides; Topoisomerase Inhibitors | 2002 |
Influence of phenytoin on the disposition of irinotecan: a case report.
Topics: Adolescent; Anticonvulsants; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Disease Progression; Drug Interactions; Enzyme Induction; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Male; Melphalan; Mixed Function Oxygenases; Neoplasm Recurrence, Local; Ondansetron; Phenobarbital; Phenytoin; Pineal Gland; Pinealoma; Prodrugs; Salvage Therapy; Seizures | 2002 |
Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Coloring Agents; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Glutathione; Humans; Inhibitory Concentration 50; Irinotecan; Mitochondrial Proteins; Mitomycin; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Proteins; RNA, Messenger; Saccharomyces cerevisiae Proteins; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2002 |
Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ.
Topics: Amino Acid Sequence; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Carrier Proteins; Caspase 3; Caspase 7; Caspase 9; Caspases; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Irinotecan; Mitochondrial Proteins; Molecular Sequence Data; Paclitaxel; Peptides; Protein Binding; Protein Structure, Tertiary; Proteins; Recombinant Fusion Proteins; Sequence Homology, Amino Acid; Tumor Cells, Cultured; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein | 2002 |
SN-38 induces cell cycle arrest and apoptosis in human testicular cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Line; Cisplatin; DNA; Etoposide; G1 Phase; Humans; In Situ Nick-End Labeling; Irinotecan; Male; Testicular Neoplasms; Tetrazolium Salts; Thiazoles | 2002 |
Unexpected pleural effusions in 3 pediatric patients treated with STI-571.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Camptothecin; Child; Combined Modality Therapy; Edema; Enzyme Inhibitors; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Lung Neoplasms; Male; Neoplasm Proteins; Neuroectodermal Tumors, Primitive; Piperazines; Pleural Effusion; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Sarcoma, Ewing; Testis; Topotecan | 2002 |
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.
Topics: Antineoplastic Agents; Bone Marrow; Camptothecin; Deoxycytidine; Docetaxel; Etoposide; Humans; Irinotecan; Leukocytes; Models, Biological; Neutrophils; Paclitaxel; Taxoids; Vinblastine | 2002 |
Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Base Pair Mismatch; bcl-2-Associated X Protein; Camptothecin; Carcinoma; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cell Death; Cell Line; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA Repair; Enzyme Inhibitors; Etoposide; Flow Cytometry; Humans; Irinotecan; Luciferases; Membrane Glycoproteins; Mice; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA, Small Interfering; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Transfection; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53 | 2003 |
[A case of isolated hepatic malignant lymphoma representing characteristic findings on radiological imaging].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Irinotecan; L-Lactate Dehydrogenase; Liver Neoplasms; Lymphoma; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Prednisolone; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2003 |
[Screening of DNA topoisomerase inhibitors].
Topics: Antineoplastic Agents; Camptothecin; Cell Cycle; DNA Topoisomerases; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Humans; Irinotecan; Topoisomerase Inhibitors; Tumor Cells, Cultured | 2004 |
[Chemotherapy for small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms | 2004 |
The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines.
Topics: Base Sequence; Camptothecin; Cell Division; Cell Line, Tumor; Colorectal Neoplasms; Cyclin-Dependent Kinases; Etoposide; Flow Cytometry; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Oligonucleotides | 2004 |
Usefulness of collagen gel droplet embedded culture drug sensitivity testing in ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Chemotherapy, Adjuvant; Cisplatin; Clinical Laboratory Techniques; Collagen; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gels; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Preparations; Recurrence; Remission Induction; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2004 |
Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Choline; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Hydrocarbons; Irinotecan; Magnetic Resonance Spectroscopy; Matched-Pair Analysis; Methane; Neuroblastoma; Predictive Value of Tests; Protons; Rats; Rats, Nude; Reproducibility of Results; Transplantation, Heterologous | 2004 |
[Clinical pathway based on evidence-based medicine (EBM) for chemotherapy for lung cancer].
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Critical Pathways; Etoposide; Evidence-Based Medicine; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Vomiting | 2004 |
Identification of a novel cardenolide (2''-oxovoruscharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: structure-activity relationship analyses.
Topics: Animals; Antineoplastic Agents; Calotropis; Camptothecin; Cardenolides; Cell Line, Tumor; Cell Proliferation; Cerebral Cortex; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Maximum Tolerated Dose; Mice; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Sodium-Potassium-Exchanging ATPase; Structure-Activity Relationship; Swine; Thiazoles | 2005 |
The effect of granisetron on in vitro metabolism of doxorubicin, irinotecan and etoposide.
Topics: Antibiotics, Antineoplastic; Antiemetics; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Culture Techniques; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Etoposide; Granisetron; Humans; Irinotecan; Microsomes, Liver | 2005 |
[Surgical treatment for locally advanced lung cancer; therapeutic response of induction chemotherapy and postoperative chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Postoperative Period; Survival Rate | 2005 |
Direct activation of the human major vault protein gene by DNA-damaging agents.
Topics: Antineoplastic Agents; Binding Sites; Butyrates; Camptothecin; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Irinotecan; Luciferases; Promoter Regions, Genetic; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Stability; RNA, Messenger; Transfection; Vault Ribonucleoprotein Particles | 2006 |
Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro.
Topics: Antigens, CD20; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; CD40 Antigens; Cell Survival; Clone Cells; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; Etoposide; Female; Flow Cytometry; Fluorouracil; Humans; Integrin alpha1; Integrin alpha6; Irinotecan; Mitomycin; Uterine Cervical Neoplasms; X-Rays | 2006 |
[A case of small-cell lung cancer effectively treated by bi-weekly administration of amrubicin].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2006 |
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Camptothecin; Carboplatin; Drug Therapy, Combination; Etoposide; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Vascular Endothelial Growth Factor A | 2006 |
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Etoposide; Fluorouracil; Gemcitabine; Gene Expression; GPI-Linked Proteins; Hepatocytes; Humans; Immunohistochemistry; Irinotecan; Membrane Glycoproteins; Organoplatinum Compounds; Oxaliplatin; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Member 10c; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor Decoy Receptors; Tumor Necrosis Factor-alpha | 2006 |
[Development of acute type, CD 8 positive adult T-cell leukemia in a carrier of hepatitis B virus--possible therapeutic effect of lamivudine combined with chemotherapy].
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carrier State; CD8-Positive T-Lymphocytes; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Hepatitis B; HTLV-I Antibodies; Humans; Irinotecan; Lamivudine; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Mitoxantrone; Nitrosourea Compounds; Pentostatin; Prednisone; Vincristine | 2006 |
[From ASCO and WCLC 2005 to clinical practice: "conventional" treatments].
Topics: Administration, Oral; Age Factors; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Mediastinoscopy; Meta-Analysis as Topic; Middle Aged; Neoplasm Staging; Palliative Care; Pneumonectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Topotecan | 2006 |
Inhibition of glutathione synthesis overcomes Bcl-2-mediated topoisomerase inhibitor resistance and induces nonapoptotic cell death via mitochondrial-independent pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Buthionine Sulfoximine; Camptothecin; Caspase 3; Caspase 7; Caspases; Cell Death; Cell Line, Tumor; DNA Topoisomerases, Type I; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Gene Expression Regulation, Leukemic; Glutathione; Humans; Irinotecan; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2006 |
[Collision cancer of squamous cell carcinoma and small cell carcinoma of the lung; report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Lung Neoplasms; Lymph Node Excision; Male; Neoplasms, Multiple Primary; Pneumonectomy | 2006 |
Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy.
Topics: Animals; Camptothecin; Carboxylesterase; Catalysis; Cell Division; Etoposide; Humans; Inhibitory Concentration 50; Irinotecan; Molecular Structure; Neuroblastoma; Prodrugs; Rabbits; Tumor Cells, Cultured | 2006 |
[A case of inoperable gastric small cell carcinoma effectively treated by chemotherapy and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Drug Combinations; Etoposide; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2006 |
Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Cytarabine; Depsipeptides; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Imatinib Mesylate; Irinotecan; K562 Cells; Leukemia; Lymphoma; Mercaptopurine; Piperazines; Pyrimidines; Time Factors | 2007 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
A non-invasive method for detection of intestinal mucositis induced by different classes of chemotherapy drugs in the rat.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breath Tests; Camptothecin; Cyclophosphamide; Disease Models, Animal; DNA Topoisomerases, Type I; Doxorubicin; Etoposide; Female; Intestine, Small; Irinotecan; Mucositis; Rats; Sucrase; Sucrose; Topoisomerase I Inhibitors | 2006 |
Protocol consisting of cisplatin, etoposide and irinotecan induced complete pathological remission of primary small cell carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Humans; Irinotecan; Male; Neoadjuvant Therapy; Remission Induction; Urinary Bladder Neoplasms | 2006 |
[Superficial small cell carcinoma of esophagus treated by endoscopic mucosal resection combined with chemoradiotherapy--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Esophagoscopes; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Mucous Membrane | 2007 |
Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Camptothecin; Child, Preschool; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Iodine Radioisotopes; Irinotecan; Neuroblastoma; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vincristine | 2008 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
DNA topoisomerase inhibitor, etoposide, enhances GC-box-dependent promoter activity via Sp1 phosphorylation.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA-Activated Protein Kinase; Enzyme Inhibitors; Etoposide; GC Rich Sequence; Humans; Irinotecan; Phosphorylation; Promoter Regions, Genetic; Sp1 Transcription Factor; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured | 2007 |
Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Camptothecin; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Etoposide; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Interferon-gamma; Irinotecan; Mitoxantrone | 2007 |
A case of small cell carcinoma of the kidney.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Kidney Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Piperidines | 2007 |
Isolated metastasis of lung cancer to the thyroid gland.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Small Cell; CD56 Antigen; Chemotherapy, Adjuvant; Chromogranin A; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Irinotecan; Lung Neoplasms; Male; Thyroid Neoplasms | 2007 |
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Endpoint Determination; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Patient Compliance; Salvage Therapy; Topotecan | 2008 |
Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Docetaxel; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2007 |
Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation?
Topics: Animals; Antineoplastic Agents; Axons; Bleomycin; Brain; Camptothecin; Cells, Cultured; Comet Assay; Embryo, Mammalian; Etoposide; Fibroblasts; Genes, Recessive; Humans; Irinotecan; Mice; Mice, Knockout; Mutation; Phosphoric Diester Hydrolases; Polyneuropathies; RNA, Messenger; Spinocerebellar Ataxias; Topotecan | 2007 |
[A case of long-term survival of postoperative brain metastasis of small cell lung cancer effectively treated with chemotherapy, whole brain radiotherapy and stereotactic radiosurgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Radiosurgery; Time Factors; Tomography, X-Ray Computed | 2008 |
Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.
Topics: Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; Etoposide; Female; Health Care Costs; Humans; Infusions, Intravenous; Insurance Claim Review; Irinotecan; Male; Middle Aged; Retrospective Studies; Topotecan; United States; Vincristine | 2008 |
Primary small cell carcinoma of the breast.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Fatal Outcome; Female; Humans; Irinotecan; Liver Neoplasms; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Thoracic Wall | 2009 |
[A case of small cell carcinoma of the ureter].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Humans; Irinotecan; Male; Ureteral Neoplasms | 2008 |
Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Immunoblotting; In Situ Nick-End Labeling; Irinotecan; Male; Mesothelioma; Mice; Mice, Nude; RNA Interference; Transfection; Xenograft Model Antitumor Assays | 2008 |
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dactinomycin; Etoposide; Fatal Outcome; Female; Foot; Groin; Humans; Ifosfamide; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Lymphatic System; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Rhabdomyosarcoma, Alveolar; Salvage Therapy; Soft Tissue Neoplasms; Sorafenib; Temozolomide; Thigh; Vincristine | 2009 |
Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Diarrhea; Drug Therapy; Drug Therapy, Combination; Enzyme Inhibitors; Ethnicity; Etoposide; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neutropenia; Polymorphism, Genetic; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Therapeutic Equivalency; Time Factors; Treatment Outcome | 2009 |
[Chemotherapy-induced myelosuppression and treatment efficacy in extensive-stage small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Carboplatin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma | 2009 |
[Chemotherapy-induced myelosuppression and treatment efficacy in limited-stage disease small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Etoposide; Female; Granulocyte Precursor Cells; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2010 |
[Hematological toxicity of some combined chemotherapy schemes involving aranoza].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Glycosides; Hematologic Tests; Irinotecan; Lymphopenia; Male; Methylnitrosourea; Mice; Mice, Inbred BALB C; Neutropenia; Topotecan | 2010 |
Poorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine: Case report.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Differentiation; Cisplatin; Deoxycytidine; Drug Administration Schedule; Endocrine Gland Neoplasms; Etoposide; Gemcitabine; Humans; Ileus; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Failure | 2010 |
Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endonucleases; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2011 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Dactinomycin; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Infratentorial Neoplasms; Irinotecan; Melphalan; Neoplasm Metastasis; Neuroblastoma; Rhabdomyosarcoma; Thiotepa; Topotecan; Vincristine | 2011 |
Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells.
Topics: Animals; Antigens; Antineoplastic Agents; Benzimidazoles; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Etoposide; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells; Peptides; T-Lymphocytes, Cytotoxic | 2011 |
A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Endonucleases; Etoposide; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinolines; Receptor, Fibroblast Growth Factor, Type 2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Risk Assessment; Small Cell Lung Carcinoma; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Wipe sampling procedure coupled to LC-MS/MS analysis for the simultaneous determination of 10 cytotoxic drugs on different surfaces.
Topics: Antineoplastic Agents; Camptothecin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Deoxycytidine; Doxorubicin; Epirubicin; Etoposide; Gemcitabine; Ifosfamide; Irinotecan; Methotrexate; Organophosphorus Compounds; Surface Properties; Tandem Mass Spectrometry; Vincristine | 2012 |
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Camptothecin; Carcinoma, Hepatocellular; Cell Death; Cell Nucleus; Cytoplasm; Deoxycytidine; Doxorubicin; Drug Synergism; Etoposide; Female; Fluorouracil; Gemcitabine; Genes, p53; Humans; Irinotecan; Liver Neoplasms; Mice; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinacrine; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Five hundred patients with Merkel cell carcinoma evaluated at a single institution.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Merkel Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Infusion Pumps; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Research Design; Skin Neoplasms; Treatment Outcome | 2011 |
Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Combined Modality Therapy; Etoposide; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; Neural Stem Cells; Oncolytic Virotherapy; Oncolytic Viruses; Simplexvirus; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2011 |
Overexpression of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; Lymphoma, B-Cell; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Polycomb Repressive Complex 1; Proto-Oncogene Proteins; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survivin; Tumor Cells, Cultured | 2012 |
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Down-Regulation; Doxorubicin; Etoposide; Floxuridine; Fluorescent Antibody Technique; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomic Instability; Humans; Irinotecan; Metaphase; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; Protein Array Analysis; Reproducibility of Results; Tegafur; Tissue Array Analysis; Tumor Cells, Cultured; Up-Regulation; Uracil | 2012 |
Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carboplatin; Cisplatin; DNA-Binding Proteins; Endonucleases; Etoposide; Female; Follow-Up Studies; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Half-Life; Humans; Irinotecan; Linear Models; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Reference Values; Remission Induction; Taxoids | 2012 |
Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy.
Topics: AC133 Antigen; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Anthracyclines; Antigens, CD; Biomarkers, Tumor; Camptothecin; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Glycoproteins; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Paclitaxel; Peptides; Receptors, Urokinase Plasminogen Activator; Retinal Dehydrogenase; RNA, Messenger; Small Cell Lung Carcinoma | 2013 |
5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma.
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Male; Neuroblastoma; Outpatients; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Salvage Therapy; Temozolomide | 2013 |
Quantification and study of the L-DOPA decarboxylase expression in gastric adenocarcinoma cells treated with chemotherapeutic substances.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Cisplatin; Dopa Decarboxylase; Dose-Response Relationship, Drug; Etoposide; Fluorouracil; Gene Expression Regulation, Enzymologic; Humans; Irinotecan; Leucovorin; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms | 2013 |
Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Necrosis; Paclitaxel; Small Cell Lung Carcinoma; Tumor Cells, Cultured | 2013 |
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Time Factors; Topotecan; Treatment Outcome | 2015 |
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cerebellar Neoplasms; Child; Child, Preschool; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Medulloblastoma; Melphalan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Quality of Life; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Young Adult | 2013 |
Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Evidence-Based Medicine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Patient Selection; Platinum Compounds; Positron-Emission Tomography | 2013 |
Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive, Peripheral; Radiotherapy; Retrospective Studies; Salvage Therapy; Vincristine; Young Adult | 2013 |
Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, University; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Long-term survival of a patient with extensive small cell carcinoma of unknown primary etiology complicated by nephrotic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Cranial Irradiation; Edema; Etoposide; Glomerulonephritis, Membranous; Humans; Irinotecan; Lymphatic Metastasis; Neoplasms, Unknown Primary; Nephrotic Syndrome; Paraneoplastic Syndromes; Pleural Effusion, Malignant; Proteinuria; Radiotherapy, Adjuvant; Remission Induction; Tomography, X-Ray Computed | 2014 |
DNA damage response (DDR) via NKX3.1 expression in prostate cells.
Topics: Acid Anhydride Hydrolases; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Cycle; Cell Line, Tumor; Cyclin D1; DNA Damage; DNA Repair; DNA Repair Enzymes; DNA-Activated Protein Kinase; DNA-Binding Proteins; Doxorubicin; Etoposide; Histones; Homeodomain Proteins; Humans; Hydrogen Peroxide; Irinotecan; Male; Metribolone; Mutagens; Phosphorylation; Prostatic Neoplasms; Protein Processing, Post-Translational; Testosterone Congeners; Transcription Factors | 2014 |
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Hospitalization; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Registries; Retrospective Studies; Survival Rate; Taxoids; United States; United States Department of Veterans Affairs; Vinblastine; Vinorelbine | 2014 |
UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Dexamethasone; Etoposide; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Recurrence; Treatment Outcome | 2015 |
Adjuvant chemotherapy in patients with completely resected small cell lung cancer: a retrospective analysis of 26 consecutive cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
Extrapulmonary small cell carcinoma in head and neck.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Combinations; Etoposide; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Radiotherapy, Adjuvant; Survival Rate; Tegafur | 2015 |
Telomerase reverse transcriptase expression protects transformed human cells against DNA-damaging agents, and increases tolerance to chromosomal instability.
Topics: Camptothecin; Cell Line, Transformed; Chromosomal Instability; DNA Breaks, Double-Stranded; DNA Damage; DNA Repair; Etoposide; Humans; Irinotecan; Mitosis; Mutation; Organoplatinum Compounds; Oxaliplatin; Recombinant Proteins; Telomerase; Telomere | 2016 |
Prognosis of small cell lung cancer patients with diabetes treated with metformin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Chemotherapy, Adjuvant; Cohort Studies; Diabetes Mellitus, Type 2; Etoposide; Female; Humans; Hypoglycemic Agents; Irinotecan; Lung Neoplasms; Male; Metformin; Middle Aged; Multivariate Analysis; Platinum Compounds; Pneumonectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Small Cell Lung Carcinoma | 2015 |
Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Camptothecin; Cisplatin; Etoposide; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Paclitaxel; Retreatment; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Lung Neoplasms; Polycomb Repressive Complex 1; RNA, Messenger | 2015 |
Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Capecitabine; Carboplatin; Carcinoma, Neuroendocrine; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Diarrhea; Digestive System Surgical Procedures; Disease-Free Survival; Etoposide; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Pelvis; Radiation Injuries; Radiodermatitis; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Rectum; Retrospective Studies; Survival Rate; Tumor Burden | 2017 |
Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2016 |
Mesenchymal stem cells exhibit resistance to topoisomerase inhibition.
Topics: Apoptosis; Camptothecin; Cell Adhesion; Cell Differentiation; Cell Movement; Cells, Cultured; Drug Resistance; Etoposide; Fibroblasts; Humans; Irinotecan; MCF-7 Cells; Mesenchymal Stem Cells; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2016 |
Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
Topics: Benzodioxoles; Binding Sites; Camptothecin; Cell Line, Tumor; Chromosome Deletion; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Gene Dosage; Guanidines; HCT116 Cells; HT29 Cells; Humans; Hydrazones; Irinotecan; Isoquinolines; Mutation | 2016 |
Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Young Adult | 2017 |
Sensitivity to
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Etoposide; Gene Expression Profiling; Glioblastoma; Humans; Irinotecan; Protein Serine-Threonine Kinases; RNA, Messenger | 2017 |
Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Camptothecin; Colonic Neoplasms; Cytarabine; Decitabine; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Etoposide; Gemcitabine; HCT116 Cells; Humans; Irinotecan; Phosphorylation | 2017 |
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Health Status; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia | 2018 |
Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pemetrexed; Progression-Free Survival; Treatment Outcome | 2018 |
Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Paclitaxel; Recurrence; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2018 |
Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cisplatin; Cytotoxicity, Immunologic; DNA Damage; Etoposide; Humans; Immunotherapy, Adoptive; Irinotecan; Killer Cells, Natural; Neuroblastoma; Reactive Oxygen Species; Topotecan; Tumor Suppressor Protein p53 | 2018 |
Mutagenicity assessment of environmental contaminations in a hospital centralized reconstitution unit.
Topics: Anthracyclines; Antineoplastic Agents; Chromatography, Liquid; Cyclophosphamide; Doxorubicin; Environmental Monitoring; Environmental Pollution; Epirubicin; Equipment Contamination; Etoposide; Hospitals; Irinotecan; Mutagenicity Tests; Salmonella typhimurium; Tandem Mass Spectrometry | 2018 |
Acute Respiratory Failure During Systemic Chemotherapy.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cecal Neoplasms; Cisplatin; Etoposide; Fatal Outcome; Female; Humans; Irinotecan; Middle Aged; Neoplastic Cells, Circulating; Respiratory Insufficiency; Thrombotic Microangiopathies | 2019 |
The clinical conundrum of managing relapsed small cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan | 2019 |
Sustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed Hepatoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Etoposide; Hepatoblastoma; Humans; Ifosfamide; Infant; Irinotecan; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Remission Induction | 2020 |
Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cyclophosphamide; Depsipeptides; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Etoposide; Histone Deacetylase Inhibitors; Histone Deacetylases; Histone Demethylases; Humans; Hydrazines; Irinotecan; Sarcoma, Ewing; Sulfonamides; Vincristine | 2019 |
Correction of Damaging Effects of Cisplatin-Containing Polychemotherapy on the Intestinal Epithelium with Tussilago farfara L. Polysaccharides.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cisplatin; Eosine Yellowish-(YS); Etoposide; Female; Hematoxylin; Histocytochemistry; Intestinal Mucosa; Irinotecan; Mice; Mice, Inbred C57BL; Paclitaxel; Plant Extracts; Polysaccharides; Tussilago | 2019 |
Adjuvant chemotherapy for patients with gastric neuroendocrine carcinomas or mixed adenoneuroendocrine carcinomas.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Propensity Score; Stomach Neoplasms; Survival Analysis | 2020 |
Successful treatment of stage 4 rhabdomyosarcoma in a female with Williams-Beuren syndrome.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Infant; Irinotecan; Neoplasm Staging; Proton Therapy; Rhabdomyosarcoma; Vincristine; Williams Syndrome | 2020 |
The AI-discovered aetiology of COVID-19 and rationale of the irinotecan+ etoposide combination therapy for critically ill COVID-19 patients.
Topics: Comorbidity; COVID-19; COVID-19 Drug Treatment; Critical Illness; Disease Outbreaks; Disease Progression; Drug Discovery; Drug Therapy, Combination; Etoposide; Humans; Irinotecan; SARS-CoV-2; Sepsis; Signal Transduction; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Treatment Outcome; Virus Internalization; Virus Replication | 2020 |
Neobavaisoflavone May Modulate the Activity of Topoisomerase Inhibitors towards U-87 MG Cells: An In Vitro Study.
Topics: Antibiotics, Antineoplastic; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Etoposide; Glioblastoma; Glutathione; Humans; Irinotecan; Isoflavones; Plant Extracts; Psoralea; Signal Transduction; Topoisomerase II Inhibitors | 2021 |
Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Etoposide; Humans; Irinotecan; Neoplasm Recurrence, Local; Neuroblastoma; Neutropenia; Retrospective Studies | 2022 |
Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Drug Resistance, Neoplasm; Etoposide; G2 Phase Cell Cycle Checkpoints; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Small Cell Lung Carcinoma; Topoisomerase Inhibitors | 2022 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |
LC-MS-MS Determination of Cytostatic Drugs on Surfaces and in Urine to Assess Occupational Exposure.
Topics: Chromatography, Liquid; Cyclophosphamide; Cytostatic Agents; Epirubicin; Etoposide; Gemcitabine; Humans; Irinotecan; Occupational Exposure; Paclitaxel; Tandem Mass Spectrometry; Vinorelbine | 2023 |
Iris metastasis as resistance mechanism to atezolizumab, carboplatin, and etoposide but responds to additional irinotecan and anlotinib in a small cell lung cancer patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blindness; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Iris; Lung Neoplasms; Small Cell Lung Carcinoma | 2023 |